# AbClon

Source: https://onco.cc/companies/abclon/  
OnCo record `abclon` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AbClon is a South Korean antibody and cell-therapy company whose CD19 CAR-T AT101 uses a newly discovered antibody binder and has shown high response rates in relapsed B-cell lymphoma.

## Summary

AbClon, listed on KOSDAQ, discovers antibodies against novel epitopes and develops them as therapeutics and CAR-T cells. AT101 is an autologous CD19 CAR-T built on the h1218 antibody, which binds a different epitope of CD19 from the FMC63 binder used in approved products; a phase 1 trial in relapsed or refractory B-cell non-Hodgkin lymphoma reported complete responses in most patients at the higher doses and a phase 2 trial is under way in Korea. AbClon also develops the HER2 antibody AC101 and a switchable CAR-T platform.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: AbClon Inc.; 앱클론; KOSDAQ:174900
- Tags: drug-maker
- HQ: Seoul
- Type: cell-therapy
- Website: https://www.abclon.com/
- Ticker: KOSDAQ:174900

## Sources

- Official website: https://www.abclon.com/

## Connected records

- drugs: [AT101](https://onco.cc/drugs/at101/)

---
JSON: https://onco.cc/api/v1/entities/abclon.json